MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of MediciNova (NASDAQ:MNOVFree Report) in a report released on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

MediciNova Stock Performance

MNOV stock opened at $1.36 on Friday. The stock has a market cap of $66.46 million, a P/E ratio of -7.97 and a beta of 0.75. The firm has a 50 day simple moving average of $1.40 and a 200 day simple moving average of $1.58. MediciNova has a 52 week low of $1.26 and a 52 week high of $2.66.

MediciNova (NASDAQ:MNOVGet Free Report) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.04. Sell-side analysts predict that MediciNova will post -0.23 EPS for the current year.

Hedge Funds Weigh In On MediciNova

An institutional investor recently bought a new position in MediciNova stock. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of MediciNova, Inc. (NASDAQ:MNOVFree Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 19,000 shares of the biopharmaceutical company’s stock, valued at approximately $28,000. Hedge funds and other institutional investors own 9.90% of the company’s stock.

MediciNova Company Profile

(Get Free Report)

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.

See Also

Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.